- Disease
- Tuesday, 23 Jun 2020
Agenus Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020
Agenus Inc., an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced that it will make a scientific presentation today on optimal anti-cancer combinations with Fc enhanced anti-CTLA-4, AGEN1181, at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting.
"AGEN1181 is an Fc-engineered anti-CTLA-4 that has shown exciting clinical activity in an early phase 1 clinical trial, which was recently presented at ASCO," said Dr. Antoine Tanne, Lead Scientist, Agenus Immune Biology Team. "Today, at AACR, we report that combinations with AGEN1181 demonstrate curative responses in preclinical models resistant to anti-PD-1. These data illustrate the potential of combining allogeneic cell therapies with checkpoint antibodies, such as AGEN1181, to deliver curative benefit in difficult to treat settings."
Related Industry Updates
Asian Stock Markets Skid as China virus toll rises to 170
Jan 30, 2020
Reinsurance: A financial Backstop for Businesses During this Pandemic?
Mar 31, 2020
China Shut Down after Death Toll rises to 11 with the contamination of Coronavirus
Jan 23, 2020
Chile Achieves WHO Verification for Elimination of Leprosy Disease
Mar 09, 2026
Coronavirus in China Sent a Ripple of Risk Aversion Through Markets
Jan 21, 2020
Managing Your Orthopaedic Care during the COVID-19 Pandemic
May 06, 2020
Epinephrine Market New Innovative Solutions To Boost Global Growth With Top Key Players- Abbott, ALK ABELLO, Amneal Pharma, Kaleo, LINCOLN MEDICAL
Jun 04, 2020